Concentra Group Holdings Parent, Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Concentra is the largest provider of occupational health services in the United States, operating 628 stand-alone occupational health centers and 413 onsite health clinics across 47 states and the District of Columbia. The company became fully independent from Select Medical Corporation following a distribution on November 25, 2024. The reporting period includes the financial impact of two major acquisitions: Nova Medical Centers (closed March 1, 2025) and Pivot Onsite Innovations (closed June 1, 2025).
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $572.8 million | $489.6 million | $1,624.3 million | $1,435.2 million |
| Net Income (Company) | $48.3 million | $44.3 million | $131.7 million | $145.0 million |
| Diluted EPS | $0.38 | $0.37 | $1.03 | $1.32 |
| Adjusted EBITDA | $118.9 million | $101.6 million | $336.6 million | $299.3 million |
| Operating Cash Flow (YTD) | $160.7 million (2025) vs $181.0 million (2024) | |||
| Cash and Equivalents | $49.9 million (as of Sept 30, 2025) | |||
| Total Debt (Carrying Value) | $1.61 billion (as of Sept 30, 2025) | |||
| Revolving Credit Availability | $393.0 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17.0% in Q3 2025 and 13.2% YTD, driven by a 9.2% increase in patient visits (Q3) and a 4.2% increase in revenue per visit. Growth was significantly bolstered by the Nova and Pivot acquisitions.
- Interest Expense: Interest expense rose sharply to $28.7 million in Q3 2025 (from $21.4 million in Q3 2024) and $82.4 million YTD (from $21.3 million in 2024). This increase is due to new term loans and senior notes issued to fund acquisitions and recapitalization, offset by the elimination of related-party debt interest with Select.
- Acquisition Impact: The company acquired Nova Medical Centers ($265 million purchase price) and Pivot Onsite Innovations ($54.4 million purchase price). These transactions added significant goodwill ($209.5 million and $34.5 million, respectively) and intangible assets.
- Operating Margins: Operating income margin decreased slightly to 16.5% in Q3 2025 from 17.6% in Q3 2024, primarily due to higher interest costs and increased general and administrative expenses related to separation and acquisition integration.
Guidance, Outlook, and Risks
Management Commentary: Management attributes revenue growth to increased volume and reimbursement rates. Adjusted EBITDA margin remained stable at 20.8% in Q3 2025. The company continues to invest in de novo centers and strategic acquisitions.
Subsequent Events & Capital Allocation:
- Debt Repayment: In October 2025, the company voluntarily repaid the remaining $35 million on its Revolving Credit Facility, leaving it with $428 million in availability.
- Share Repurchase: On November 5, 2025, the Board authorized a $100 million share repurchase program expiring December 31, 2027.
- Dividends: A quarterly dividend of $0.0625 per share was declared, payable in December 2025.
Risks and Contingencies:
- Litigation: The company faces ongoing investigations, including a California Department of Insurance subpoena regarding billing practices and a consolidated class action lawsuit related to a 2023 data breach at a third-party vendor (Perry Johnson & Associates).
- Regulatory: Risks include changes in workers' compensation fee schedules, state regulations on the corporate practice of medicine, and potential impacts from new U.S. tariff policies.
- Interest Rate Risk: The company has hedged $600 million of its variable-rate debt via swaps and collars, but remains exposed to rate fluctuations on the remaining $645.3 million of term loans and revolver.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and revenue contributions from the Nova and Pivot acquisitions against pro forma expectations.
- Debt Servicing: Monitor the impact of elevated interest rates on net income, given the significant increase in debt load to fund growth.
- Litigation Exposure: Track the status of the California insurance investigation and the Perry Johnson data breach litigation for potential material financial impact.
- Reimbursement Rates: Confirm the sustainability of the 4.2% increase in revenue per visit, which relies on state fee schedule adjustments.
- Liquidity Position: Assess the company's ability to fund the new $100 million share repurchase program while maintaining adequate working capital and debt covenants (current leverage ratio is 3.6x).